Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

NCT07247266 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Cryopyrin-associated Periodic Syndromes (CAPS)

Interventions

DRUG: JTE-162

Sponsor

Akros Pharma Inc.

Collaborators

[object Object]